Dndi's sunflower classic

Source: US and Chinese drug sources yesterday, August 29, 2016, Nature reported a new model of developing new drugs by dndi (drugs for emerging diseases initiatives) In just over 10 years, dndi has launched six new drugs with us $290 million and 26 in clinical research The group says its model costs an average of $110-170 million to develop a new drug, far less than the $2.6 billion cost of a new drug for the pharmaceutical industry Their leaders claim that the model can be learned by other drug development agencies, not just by infectious diseases in Africa The R & D efficiency of large pharmaceutical companies has been widely criticized Although the efficiency of pharmaceutical companies has been improving slowly, investors are still very interested in cost saving If there is a magic R & D model that can reduce the cost by 80%, then pharmaceutical companies will definitely learn to adopt it with open mind If this model can control the cost of developing mainstream new drugs to less than 200 million dollars, it is no different from the Wulin script Now the living conditions in the pharmaceutical industry are so dangerous Will anyone else take the risk of falling into the devil to practice toad skill when sunflower Scripture has been put online for free? Although this model can greatly reduce costs, it also has to pay an important price Similar to sunflower, this model requires manufacturers and investors to be prepared to give up the lifeblood of profits The drugs developed by dndi are all tropical infectious diseases with a large population but few standard therapies Because there is no standard therapy, the effect is easy to achieve Because infectious diseases only need short-term treatment, so the safety requirements are low In addition, it is much simpler in mechanism to deal with microbial infection than to recover human dysfunction, so the probability of failure is also low Most of these diseases occur in poor Africa Even if the investment is small, the manufacturers can not get enough profits So dndi is undoubtedly doing a great job, but it's a bit exaggerated to say that they have found a more effective way to find new drugs In addition to no profit pressure to have more freedom to choose projects, they are free of charge from many pharmaceutical factories, universities, other institutions to provide high-quality compounds (many have entered the clinical), screening platforms, clinical trials and other funding They say it's only 10-20%, but some suspect they're paying Investors invest in pharmaceutical companies in return, and this has been the case since they owned them So those diseases that can bring returns, such as cancer, diabetes and heart disease, have been invested with many kinds of drugs for many years in a row If new drugs want to show their advantages and get returns, they must take greater risks and do more expensive clinical trials A while ago, mosadon gave up DPP4 inhibitor once a week after more than 8000 clinical trials, not because the drug was ineffective, but because it could not survive in the crowded market Many drugs, such as the anticoagulant zontivity and hepatitis C drug incivek, have been squeezed out of the market by better drugs after the manufacturers invested a lot of capital to go on the market Also, in order to lead in the fierce competition, many projects need to take risks in the case of incomplete data and increase the probability of failure Now there are a number of phase I clinical trials of more than 200 people ready for the market, which was unimaginable 10 years ago These costs are not considered by dndi In order to promote his sunflower Scripture, dndi's head even came up with a way to help the manufacturers, that is, the government or an organization decide which diseases need treatment and which manufacturers and organizations can cooperate He said that the profit-seeking new drug development model not only has a high failure rate, but also ignores the pain of most patients Thank God he's just in charge of dndi